Title: Activated Autologous Platelet Rich Plasma Therapy in the management of Chronic Non Healing Diabetic Foot Ulcer: One Centre Study from Bangladesh
Authors: Dr Md. Ashraful Hoque, Dr Shahnewaz Parvez, Dr Tamanna Afroz
DOI: https://dx.doi.org/10.18535/jmscr/v7i6.54
Abstract
Foot ulcers caused by diabetes are most important causes of limb amputations especially lower limb in Bangladesh. Treatment of foot ulcers by conventional way often causes hospitalization for long periods results in huge burden to many people. Use of platelet-rich plasma (PRP) mainly by autologous, that is rich in various growth factors, bear some equivalence to the uniform wound healing. Some studies on human are so far showed the potentiality of PRP as a unique and minimally invasive procedure. We included ten case with non healing diabetic foot ulcers, not responding to conventional treatment modalities, was efficiently treated by PRP.
Patients and Methods: This study has included 25 patients of both sex ages from 18 to 60 years, with chronic no healing diabetic foot ulcers. These patients were treated with autologous platelet rich plasma activated by calcium gluconate. Few patients needed 2 times PRP therapy but most of the patients needed just one schedule.
Results: Healing rate was much higher in PRP treated group than conventional group. Improvement was visible after 2 weeks in PRP treated group was because angiogenesis required time to generate.
Conclusion: Activated autologous PRP therapy is more effective than conventional therapy.
Keywords: Platelet Rich Plasma, Autologous, Activation, Calcium Gluconate, Centrifugation, Granulation
References
- About diabetes" World Health Organization. Archived from the original on 31 March 2014. Retrieved 4 April 2014.
- "Diabetes Fact sheet N°312". WHO. October 2013. Archived from the original on 26 August 2013. Retrieved 25 March 2014.
- Kitabchi AE, Umpierrez GE, Miles JM, Fisher JN (July 2009). "Hyperglycemic crises in adult patients with diabetes". Diabetes Care. 32 (7): 1335–43.
- Abredari H, Bolourchifard F, Rassouli M, Nasiri N, Taher M, (2015) Health locus of control and self-care behaviors in diabetic foot patients. Med J Islam Repub Iran 26: 283.
- Kadam D (2016) Microsurgical reconstruction of plantar ulcers of the insensate J Reconstr Microsurg 32: 402-410.
- Hicks CW, Selvarajah S, Mathioudakis N, Sherman RE, Hines K (2016) Burden of infected diabetic foot ulcers on hospital admissions and costs. Ann Vasc Surg 33: 149-158.
- Zhang Z, Lv L (2016) Effect of local insulin injection on wound vascularization in patients with diabetic foot ulcer. Exp Ther Med 11: 397-402.
- Picard F, Hersant B, Bosc R, Meningaud JP (2015) The growing evidence for the use of platelet-rich plasma on diabetic chronic wounds: A review and a proposal for a new standard care. Wound Repair Regen 23: 638-643.
- Yotsu RR, Hagiwara S, Okochi H, Tamaki T (2015) Case series of patients withchronic foot ulcers treated with autologous platelet-rich plasma. J Dermatol 42:288-295.
- Mehrannia M, Vaezi M, Yousefshahi F, Rouhipour N (2014) Platelet rich plasma for treatment of nonhealing diabetic foot ulcers: A case report. Can J Diabetes 38 5-8.
- de Leon JM, Driver VR, Fylling CP, Carter MJ, Anderson C, et al. (2011) The clinical relevance of treating chronic wounds with an enhanced near-physiological concentration of platelet-rich plasma gel. Adv Skin Wound Care.24 357-368.
- Scimeca CL, Bharara M, Fisher TK, Kimbriel H, Armstrong DG (2010) Novel use of platelet-rich plasma to augment curative diabetic foot surgery. J Diabetes Sci Technol 4: 1121-1126.
- Driver VR, Hanft J, Fylling CP, Beriou JM; Autologel Diabetic Foot Ulcer Study Group (2006) A prospective, randomized, controlled trial of autologous platelet-rich plasma gel for the treatment of diabetic foot ulcers. Ostomy Wound Manage 52: 68-70.
- Lacci K.M, Dardik A (2010) Platelet-rich plasma: Support for its use in wound Yale J Biol Med 83: 1–9.
- Belecki TM, Arendt J, Szczepanski T, Krol W, Wielkoszynski T (2007) Antibacterial effect of autologous platelet gel enriched with growth factors and other active substances: An in vitro study. J Bone Joint Surg Br 89: 417–420.